S
QTTB icon

Sanofi’s Q32 Bio QTTB Stock Holding History

Sanofi’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.57M Hold
244,083
– – 0.47% 9
2025
Q4 		$810K Hold
244,083
– – 0.26% 8
2025
Q3 		$483K Hold
244,083
– – 0.19% 9
2025
Q2 		$364K Hold
244,083
– – 0.21% 10
2025
Q1 		$403K Hold
244,083
– – 0.24% 9
2024
Q4 		$840K Buy
+244,083
New +$7.71M 0.48% 9

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Sanofi's QTTB Position: Q1 2026 in Review

Sanofi held its Q32 Bio (QTTB) position steady in Q1 2026 at 244,083 shares worth $1.57M. The position accounts for 0.47% of the portfolio, ranked #9.

Sanofi first reported a position in QTTB in Q4 2024 and has held it in 6 quarters since. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Sanofi held 244,083 shares of Q32 Bio worth $1.57M as of Q1 2026.
  • Sanofi left its Q32 Bio share count unchanged in Q1 2026.
  • Q32 Bio made up 0.47% of Sanofi's portfolio in Q1 2026, its #9 holding.
  • Sanofi first reported a position in Q32 Bio in Q4 2024 and has held it in 6 quarters since.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Sanofi's 13F filing for Q1 2026, filed 7 May 2026.